Optical and clinical outcomes of a new diffractive trifocal intraocular lens

Abstract

Purpose

To optically characterize and clinically evaluate the new trifocal AT ELANA 841P intraocular lens (IOL).

Methods

The optical imaging performance was assessed using an on-bench model eye through the Through-Focus Modulation Transfer Function Area (TF-MTFa) from +1.00 to −3.50D. The clinical study included manifest refraction, uncorrected (UDVA) and corrected (CDVA) distance visual acuities, distance-corrected intermediate (DCIVA) and near visual acuity (DCNVA), binocular photopic and mesopic contrast sensitivity (CS) and binocular defocus curve. Postoperative evaluation was performed 3 months after surgery.

Results

Optimal optical quality is observed at the distance focus on the TF-MTFa curve. From there, optical quality continuously degrades, initially rapid up to approximately −0.75D, then much slower extending to −2.0D. Subsequently, optical quality improves before a decline from −2.75D. The clinical study involved 40 patients. The mean postoperative monocular UDVA and CDVA were 0.04 ± 0.05 and 0.01 ± 0.02 logMAR, respectively. All eyes achieved a monocular UDVA of 0.2 logMAR or better and a monocular CDVA of 0.1 logMAR or better. All patients reached a binocular DCNVA of 0.2 logMAR or better, and 95% achieved a DCIVA of 0.2 logMAR or better. The defocus curve yielded a range from +0.50 to −2.5D, in which the mean visual acuity was 0.1 logMAR or better. The binocular distance CS was within normal limits.

Conclusions

The implantation of the new AT ELANA IOL provided a satisfactory range of visual quality from distance to near, in excellent agreement with the IOL optical performance obtained with the on-bench model eye.